Significant Pharmaceuticals Reported in US Patents

Thomas F. DeRosa

• Publisher: Elsevier Science
• Year: 2010
• eBook ISBN: 9780080480916
• Topic: Physical Sciences
• Subtopic: Analytic Chemistry

Significant Pharmaceuticals Reported in US Patents identifies the next generation of pharmaceuticals reported in US Patents. This "hands-on" title provides explicit laboratory methods for preparing the most recent and effective medications. Each entry documents the biological testing protocols used to evaluate a drug and the significance of the current treatment agent over previous methods. Pharmaceuticals are included in this review only if at least two of the following criteria were met: Effectiveness in treating an illness, Innovative, ease of preparation, synergy with existing Medications. Pharmaceuticals are reported for 27 separate classes of illness, including: AIDS, Alzheimer's Disease, Cardiovascular Disorders, Diabetes, Epilepsy, Hepatitis C, Osteoporosis, Obesity and Sleep Disorders. Significant Pharmaceuticals Reported in US Patents has been designed to be used as both a reference and synthetic guide for pharmaceutical, medicinal and organic chemists and graduate students. Researchers working in other areas will also find the information valuable as in many instances intermediates or the next generation pharmaceutical are readily convertible into other industrial products including: anti-oxidants, chemical additives, herbicides, polymer precursors, water purification agents. Clear structural depictions of reagents and chemical transformations have been supplied to permit the identification of other future applications. - Identifies next generation pharmaceuticals - Provides practical preparation methods for each active agent and derivatives - Documents the analytical characterization and biological testing results of active agents

Chapter I

Acquired Immune Deficiency Syndrome

I Antioxidants, Preparation Methods, and Uses

Title Antioxidants, Preparation Methods and Uses
J. Oiry et al., US Patent 6,989,372 (January 24, 2006)

Assignee Centre National de la Recherche Scientifique and Commissariat a l'Engergie Atomique

Utility Treatment of Pathologies Associated with Glutathione Depletion

Invention Significance Reactive oxygen species play an important role in human pathologies and are particularly associated with retroviral infections such as human immunodeficiency virus (HIV). Intracellular defense against oxidative species is controlled by glutathione. To contain these reactive oxygen species effects, free radical scavengers have been prepared that increase glutathione reserves.

Reaction

Eq. 1

i- N-Methylmorpholine, isobutyl chloroformate, EtOAc, S-acetylcysteamine · HCl

ii- Methyl alcohol, CHCl₃, silver nitrate, pyridine

iii- CHCl₃, hydrochloric acid

Experimental

1. Preparation of N-(N-acetyl-S-trityl-l-cysteinyl)-S-acetylcysteamine
A solution of N-acetyl-S-trityl-l-cysteine (0.71 mmol) and 80μ1 N-methylmorpholine dissolved in 5 ml of EtOAc was stirred at–15°C, then treated with 93μl isobutyl chloroformate. After 15 minutes, S-acetylcysteamine hydrochloride (0.71 mmol) and an additional 80μl N-methyl-morpholine were added and the mixture stirred for 15 minutes at – 15°C and then 3 hours at ambient temperature. N-Methylmorpholine hydrochloride was then filtered off and the mixture was washed twice with 2.5 ml of EtOAc and concentrated. The gummy residue was purified by flash chromatography with silica gel using EtOAc/30% petroleum ether and the product isolated in 55% yield as a colorless powder, mp=111−113°C.
R_f = 0.41, EtOAc/petroleum ether, 9:1
[α]_D²⁰=+10.5° (c. 0.8, CHCl₃
¹H NMR (CDCl₃) δ (ppm) 1.90 (s, 3H, NCOCH₃), 2.29 (s, 3H, SCOCH₃), 2.48 (dd, J = 5.7, 12.9Hz, 1H, β Ha cys), 2.82 (dd, J = 6.4, 12.9Hz, 1H, β Hb cys), 2.92–3.01 (m, 2H, NCH₂CH₂S), 3.32–3.42 (m, 2H, NCH₂CH₂S), 4.07–4.20 (m, 1H, α H cys), 5.70 (d, J = 7.6Hz, 1H, NH cys), 6.34 (t, J = 5.5Hz, 1H, NHCH₂), 7.19–7.35 and 7.40–7.47 (2m, 15H, aromatic H)
MS (FAB +/NBA + K +) m/z 545 (M + K)⁺, 507 (M + H)⁺; (FAB-/NRA) m/z 505 (M-H)⁻
Analysis Calc. for C₂₈H₃₀N₂O₃S₂ (506): C, 66.40; H, 5.93; N, 5.53. Found: C, 66.17; H, 6.00; N, 5.81

2...

Table of contents

• Cover image
• Title page
• Table of Contents
• Copyright page
• Dedication
• Introduction
• Chapter I: Acquired Immune Deficiency Syndrome
• Chapter II: Addiction Disorders
• Chapter III: Alzheimer's Disease
• Chapter IV: Analgesics
• Chapter V: Antibacterial Agents
• Chapter VI: Anti-inflammatory Agents
• Chapter VII: Autoimmune Disorders
• Chapter VIII: Cardiovascular Disorders
• Chapter IX: Diabetes
• Chapter X: Diagnostics
• Chapter XI: Epilepsy
• Chapter XII: Gastrointestinal Disorders
• Chapter XIII: Hepatitis C
• Chapter XIV: Hormonal Disorders
• Chapter XV: Immunosuppressants
• Chapter XVI: Improved Synthetic Methods
• Chapter XVII: Incontinence
• Chapter XVIII: Irritable Bowel Syndrome
• Chapter XIX: Malaria
• Chapter XX: Migraine Headaches
• Chapter XXI: Obesity
• Chapter XXII: Ocular Disorders
• Chapter XXIII: Osteoporosis
• Chapter XXIV: Parkinson's Disease
• Chapter XXV: Proliferative Disorders
• Chapter XXVI: Psychiatric
• Chapter XXVII: Skin Disorders
• Chapter XXVIII: Sleep Disorders
• Chapter XXIX: Thyroid Disorders
• Chapter XXX: Tinnitus
• Appendix: Patent Assignees
• Index